Shifting Paradigms in Drug Development: The Latest in Health News

The latest health news features the FDA's move to expedite biosimilar drugs, Roche's trial disappointment, and US-China tensions over drug trade. Hims & Hers partners with Novo Nordisk, increasing its stock value. Meanwhile, efforts to improve kidney transplant inequity among Black patients are making progress.

The U.S. Food and Drug Administration is proposing changes to its testing guidelines to expedite the development of biosimilar drugs. This move is designed to encourage the creation of more affordable medicines and address the high costs associated with biologic drugs.

In other news, Swiss pharmaceutical giant Roche saw a significant drop in its shares after its breast cancer drug, giredestrant, failed to meet expectations in clinical trials. The trial did not demonstrate improved outcomes compared to standard treatments.

The U.N. drugs meeting recently highlighted the ongoing friction between the U.S. and China, underscoring accusations regarding fentanyl precursor chemicals and trade issues. These developments come amidst a backdrop of significant legal and business maneuvers in the pharmaceutical sector.

(With inputs from agencies.)